Both GSK and HLN are falling due to worries about litigation over the Zantec drug.
Technically, HLN has nothing to do with it after demerger but yahoo news has reported that:
Haleon said it has certain indemnification obligations to GSK and Pfizer, “which may include liabilities related to OTC Zantac,” in a prospectus ahead of listing its shares in London last month. That’s while Credit Suisse analysts flagged Haleon’s involvement in Zantac litigation was limited.
Anyway, I bought some more Haleon today. This could be possible falling knife territory or it may be that the market is over-reacting to Haleon's possible exposure to the Zantec Litigation.
No comments:
Post a Comment